TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30130032

Group type: EXPERIMENTAL
Intervention: Reminders both 3 days and 1 day prior to the visit
Number of subjects: 54066

Group type: COMPARATOR
Intervention: 3-day reminder
Number of subjects: 54066

Group type: COMPARATOR
Intervention: 1-day reminder
Number of subjects: 54066

Group type: EXPERIMENTAL
Intervention: Reminders both 3 days and 1 day prior to the visit (high risk patients)
Number of subjects: 54066

Group type: COMPARATOR
Intervention: 3-day reminder (high risk patients)
Number of subjects: 54066

Group type: COMPARATOR
Intervention: 1-day reminder (high risk patients)
Number of subjects: 54066
Study: 27498606

Group type: EXPERIMENTAL
Intervention: Active tDCS (5 days, 20 minutes per session, 2 mA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS (1 day real, 4 days sham)
Number of subjects: 30
Study: 25546356

Group type: EXPERIMENTAL
Intervention: (‐)‐epicatechin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: procyanidin B1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: polymeric procyanidins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gut microbiota metabolism
Number of subjects: 0
Study: 22944077

Group type: EXPERIMENTAL
Intervention: Lesser tuberosity osteotomy (LTO)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 87
Study: 19787380

Group type: EXPERIMENTAL
Intervention: Infusion set (500-cc solution bag with gravity-driven delivery)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Infusion pump
Number of subjects: 27
Study: 18401766

Group type: EXPERIMENTAL
Intervention: Glucerna
Number of subjects: 203

Group type: COMPARATOR
Intervention: Fresubin
Number of subjects: 203
Study: 15937041

Group type: EXPERIMENTAL
Intervention: Transdermal secretin applied daily in ointment form for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo applied daily in ointment form for 4 weeks
Number of subjects: 15
Study: 15344899

Group type: EXPERIMENTAL
Intervention: Prerandomization computerized tomography (CT) scans
Number of subjects: 0
Study: 10987150

Group type: EXPERIMENTAL
Intervention: Exercise therapy (active and passive jaw movement exercises, correction of body posture, and relaxation techniques)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 30
Study: 8988067

Group type: EXPERIMENTAL
Intervention: Watercress + Acetaminophen
Number of subjects: 7
Study: 1455306

Group type: EXPERIMENTAL
Intervention: Octreotide 150 micrograms subcutaneously every 8 hours
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline solution subcutaneously every 8 hours
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Octreotide and Saline solution
Number of subjects: 21
Study: 6365349

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 126
Study: 30858012

Group type: EXPERIMENTAL
Intervention: Quetiapine-ER
Number of subjects: 113

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 113
Study: 29933559

Group type: EXPERIMENTAL
Intervention: Yogurt fermented with Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 26959482

Group type: EXPERIMENTAL
Intervention: Vitamin D 3 1,000 IU daily for 6 months
Number of subjects: 96
Study: 25149431

Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara (MVA) vaccine administered by subcutaneous injection at Week 0 and 4
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara (MVA) vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study: 22240180

Group type: EXPERIMENTAL
Intervention: Intraoperative music added to routine pain control measures (ibuprofen and paracervical block)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Routine pain control measures only (ibuprofen and paracervical block)
Number of subjects: 101
Study: 20416451

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg oral tablets daily for one month
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 17687689

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: doxepine 10 mg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: hydroxyzine 25 mg/day
Number of subjects: 75
Study: 16329418

Group type: EXPERIMENTAL
Intervention: Vitremer (3M Dental Products)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: F2000 Compomer (3M Dental Products)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dyract AP (Dentsply DeTrey)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valux Plus (3M Dental Products)
Number of subjects: 30
Study: 16881161

Group type: EXPERIMENTAL
Intervention: Mother-infant intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9495433

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 1 min before intubation
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 3 min before intubation
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 5 min before intubation
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fentanyl (2 microg/kg) administered 10 min before intubation
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 170
Study: 7787368

Group type: EXPERIMENTAL
Intervention: Health Structure Regulation (law enacted in 1992)
Number of subjects: 0
Study: 2668060

Group type: EXPERIMENTAL
Intervention: 3 days treatment with amoxycillin (1.5 g/day)
Number of subjects: 10909

Group type: COMPARATOR
Intervention: 10 days therapy (750 mg amoxycillin/day)
Number of subjects: 10909
Study: 1213890

Group type: EXPERIMENTAL
Intervention: Topical treatment with estrogen in an alcoholic vehicle (0.05% dienestroldiacetate) applied daily on the scalp skin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Corresponding preparation without estrogen (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical treatment with estrogen
Number of subjects: 30
Study: 31091575

Group type: EXPERIMENTAL
Intervention: Low dose remifentanil (Group L)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High dose remifentanil (Group H)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High dose remifentanil with gradual withdrawal (Group G)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group H)
Number of subjects: 90
Study: 27152677

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 802

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 802
Study: 25520333

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention protocol (manual tooth/gum brushing plus 0.12% chlorhexidine oral rinse, twice per day, plus upright positioning during feeding)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention protocol
Number of subjects: 834
Study: 23930160

Group type: EXPERIMENTAL
Intervention: Swedish massage (10-15 min, 3 times a week for 10 sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no massage, relaxed in the same environment)
Number of subjects: 50
Study: 21777835

Group type: EXPERIMENTAL
Intervention: Intercoat gel (polyethylene oxide-sodium carboxymethylcellulose) applied intrauterinely during hysteroscopic surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (hysteroscopic surgery only)
Number of subjects: 110
Study: 18570693

Group type: EXPERIMENTAL
Intervention: Light exercise (100 min at 30 % of peak oxygen consumption; net energy expenditure 1.04 (sem 0.01) MJ) plus mild energy intake restriction (1.39 (sem 0.22) MJ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (resting coupled with isoenergetic feeding)
Number of subjects: 8
Study: 17039510

Group type: EXPERIMENTAL
Intervention: Gold-coated stents
Number of subjects: 731

Group type: COMPARATOR
Intervention: Uncoated stents
Number of subjects: 731
Study: 15105064

Group type: EXPERIMENTAL
Intervention: LNG IUS
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral Contraceptives (OCs)
Number of subjects: 200
Study: 12116891

Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg caplets and i.v. argatroban 1.5 micrograms/kg/min
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg/hr and i.v. argatroban 1.5 micrograms/kg/min
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral digoxin 0.375 mg/day and i.v. argatroban 2 micrograms/kg/min
Number of subjects: 35
Study: 9525449

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7712753

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (parenteral cefotaxime, oral and enteral polymyxin E, amphotericin B, tobramycin)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: No selective decontamination
Number of subjects: 1528
Study: 2568299

Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 363631

Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 27271374

Group type: EXPERIMENTAL
Intervention: MitiiTM training (20 weeks, 30 minutes/day, six days/week, total 60 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care control group (waitlisted for 20 weeks)
Number of subjects: 60
Study: 25806674

Group type: EXPERIMENTAL
Intervention: 2.25% carbachol plus 0.2% brimonidine eye drops
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 48
Study: 23748458

Group type: EXPERIMENTAL
Intervention: Laser therapy at a dose of 4 J/cm²
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Needling with 2% lidocaine injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 20547464

Group type: EXPERIMENTAL
Intervention: Hot water immersion trial (HIT; 47.5°C) of 2 min duration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inter-digital web pinching (IWP; 15N)
Number of subjects: 24
Study: 18954363

Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK)
Number of subjects: 68

Group type: COMPARATOR
Intervention: University of Wisconsin (UW)
Number of subjects: 68
Study: 17885992

Group type: EXPERIMENTAL
Intervention: Idea improvement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Idea imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Source-monitoring test
Number of subjects: 0
Study: 15136680

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study: 11480162

Group type: EXPERIMENTAL
Intervention: Positive affect imagery with external imagery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Positive affect imagery with internal imagery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Negative affect imagery with external imagery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Negative affect imagery with internal imagery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 50
Study: 9643685

Group type: EXPERIMENTAL
Intervention: Primary stent placement (group I, n=143)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Primary angioplasty followed by selective stent placement (group II, n=136)
Number of subjects: 279
Study: 8172700

Group type: EXPERIMENTAL
Intervention: Vestibular training (VT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VT with medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VT without medication
Number of subjects: 0
Study: 31863245

Group type: EXPERIMENTAL
Intervention: Hierarchical Poincaré analysis using Poincaré‐index20‐30 Hz combined with Poincaré‐index0.5‐47 Hz
Number of subjects: 30

Group type: COMPARATOR
Intervention: Original Poincaré‐index0.5‐47 Hz
Number of subjects: 30
Study: 30862667

Group type: EXPERIMENTAL
Intervention: JT010 (TRPA1 agonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: A-967079 (TRPA1 antagonist)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27590442

Group type: EXPERIMENTAL
Intervention: Top quartile of satisfaction with care coordination and quality
Number of subjects: 23470

Group type: EXPERIMENTAL
Intervention: Top quartile of satisfaction with access to medical care
Number of subjects: 23470
Study: 25807891

Group type: EXPERIMENTAL
Intervention: Rapid Syllable Transition (ReST) treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nuffield Dyspraxia Programme‐Third Edition (NDP3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both ReST and NDP3
Number of subjects: 26
Study: 23698063

Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy (ART)
Number of subjects: 3280
Study: 21372309

Group type: EXPERIMENTAL
Intervention: FES-induced cycling training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo FES cycling
Number of subjects: 35
Study: 18165562

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.085 microg x kg(‐1) x min(‐1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: N2O 66%
Number of subjects: 70
Study: 16877621

Group type: EXPERIMENTAL
Intervention: Continuous consent process
Number of subjects: 30
Study: 12538746

Group type: EXPERIMENTAL
Intervention: Cyclosporine treatment for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for 24 weeks
Number of subjects: 0
Study: 11142481

Group type: EXPERIMENTAL
Intervention: Alternating regimen of bolus and continuous infusion 5-FU (200 mg/m2 continuous infusion) + weekly bolus 6-S-leucovorin (20 mg/m2)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control arm: biweekly cycles of MTX (200 mg/m2 on day 1) followed by bolus 5-FU (600 mg/m2 on day 2) + 6-S-leucovorin rescue
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 214
Study: 9095423

Group type: EXPERIMENTAL
Intervention: Once-daily wound cleansing and dressing change
Number of subjects: 50

Group type: COMPARATOR
Intervention: Twice-daily dressing changes (Control)
Number of subjects: 50
Study: 8242966

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (mean optimal dose of 2.7 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Columbia rating scale and quantitative assessments (tapping, walking, pinboard)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Domperidone pretreatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3728294

Group type: EXPERIMENTAL
Intervention: Intravenous procainamide
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous quinidine
Number of subjects: 51
Study: 29397328

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE; 4 × 4 minutes; 85%-95% HRpeak; 24 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE; 24 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE-T; 16 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE; 50 minutes; 70% HRpeak; 24 sessions)
Number of subjects: 0
Study: 26527417

Group type: EXPERIMENTAL
Intervention: A4250 3 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: A4250 1.5 mg twice daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: A4250 0.1, 0.3, 1, 3, or 10 mg (single administration)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24866613

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 24
Study: 21620515

Group type: EXPERIMENTAL
Intervention: Standard care plus pGlcNAc applied once
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Standard care plus pGlcNAc applied every other week
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Standard care plus pGlcNAc applied every 3 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 82
Study: 19669586

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 19094432

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil (0.3 - 0.6 microg/kg per min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous fentanyl (5 - 10 microg/kg per h)
Number of subjects: 40
Study: 15663590

Group type: EXPERIMENTAL
Intervention: Live lactobacilli in combination with low dose oestriol (Gynoflor)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 12391951

Group type: EXPERIMENTAL
Intervention: Computerized guidelines
Number of subjects: 139

Group type: COMPARATOR
Intervention: Paper-based guidelines
Number of subjects: 139
Study: 10745532

Group type: EXPERIMENTAL
Intervention: Outpatient strategy (n = 43)
Number of subjects: 262

Group type: COMPARATOR
Intervention: In-patient strategy (n = 47)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Satisfaction survey for all patients and family members
Number of subjects: 262
Study: 7872940

Group type: EXPERIMENTAL
Intervention: Standard instruction ('count all heartbeats you feel in your body')
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Exposure treatment in a subgroup of 40 patients
Number of subjects: 112
Study: 2350208

Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Controls (normal volunteers)
Number of subjects: 10
Study: 247895

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus tobramycin (TT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Carbenicillin plus gentamicin (CG)
Number of subjects: 82
Study: 31478799

Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 14848

Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 14848

Group type: EXPERIMENTAL
Intervention: DBT
Number of subjects: 14848
Study: 27777061

Group type: EXPERIMENTAL
Intervention: 5% KNO3/3% O/MA dentifrice
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 5% KNO3 dentifrice (active comparator)
Number of subjects: 139

Group type: COMPARATOR
Intervention: 0% KNO3/3% O/MA dentifrice (placebo)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Regular fluoride dentifrice (negative control)
Number of subjects: 139
Study: 24796714

Group type: EXPERIMENTAL
Intervention: Oral health educational program (90-min every 2 weeks for 3 months)
Number of subjects: 47

Group type: COMPARATOR
Intervention: General information about oral health (control group)
Number of subjects: 47
Study: 23866850

Group type: EXPERIMENTAL
Intervention: Psychosocial care during radiotherapy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Radiotherapy only (Control)
Number of subjects: 178
Study: 21640779

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given simultaneously
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given 30 days apart
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine
Number of subjects: 1769
Study: 19120333

Group type: EXPERIMENTAL
Intervention: Medium-dose UVA1 phototherapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Narrowband UVB phototherapy
Number of subjects: 28
Study: 16829185

Group type: EXPERIMENTAL
Intervention: Levosimendan (12 microg/kg followed by a continuous infusion of 0.1-0.2 microg/min)
Number of subjects: 22
Study: 15054439

Group type: EXPERIMENTAL
Intervention: 1.5 g taurine daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11096237

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4222
Study: 9068025

Group type: EXPERIMENTAL
Intervention: Modified formula (MF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional formula (CF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both MF and CF
Number of subjects: 12
Study: 8371204

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) interrupted 7 days before surgery (Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Methotrexate (MTX) not discontinued (Group B)
Number of subjects: 64
Study: 3520132

Group type: EXPERIMENTAL
Intervention: Minoxidil, 2.5 mg twice daily (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Captopril, 25 mg twice daily (n = 11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Minoxidil after switch from captopril
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Captopril after switch from minoxidil
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Minoxidil vs Captopril
Number of subjects: 23
Study: 31733985

Group type: EXPERIMENTAL
Intervention: Inhaler drug education
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no inhaler drug education)
Number of subjects: 85
Study: 31538602

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 206

Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 206
Study: 29782200

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 27454090

Group type: EXPERIMENTAL
Intervention: simvastatin 40mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40mg/day
Number of subjects: 30
Study: 24170913

Group type: EXPERIMENTAL
Intervention: Nasal PEP breathing
Number of subjects: 20